Page last updated: 2024-09-04
bz-423 and plx4032
bz-423 has been researched along with plx4032 in 1 studies
Compound Research Comparison
| Studies (bz-423) | Trials (bz-423) | Recent Studies (post-2010) (bz-423) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
|---|---|---|---|---|---|
| 56 | 0 | 14 | 1,657 | 103 | 1,587 |
Protein Interaction Comparison
| Protein | Taxonomy | bz-423 (IC50) | plx4032 (IC50) |
|---|---|---|---|
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Lilla, C; Livingstone, E; Roesch, A; Schadendorf, D; Swann, S | 1 |
Other Studies
1 other study(ies) available for bz-423 and plx4032
| Article | Year |
|---|---|
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydrazines; Imidazoles; Indoles; Melanoma; Metformin; Mitochondria; Oxidative Phosphorylation; Oximes; Phenformin; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2015 |